Polar Asset Management Partners Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Polar Asset Management Partners Inc.

  • $2.98 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$38.96 - $42.75 $584,400 - $641,250
-15,000 Reduced 60.0%
10,000 $408,000
Q1 2024

May 15, 2024
BUY
$40.88 - $43.27 $1.02 Million - $1.08 Million
25,000 New
25,000 $1.06 Million
Q4 2023

Feb 14, 2024
SELL
$20.27 - $42.44 $149,998 - $314,056
-7,400 Reduced 15.61%
40,000 $1.7 Million
Q3 2023

Nov 14, 2023
BUY
$20.26 - $31.91 $960,324 - $1.51 Million
47,400 New
47,400 $1.03 Million

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Polar Asset Management Partners Inc. Portfolio

Follow Polar Asset Management Partners Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Asset Management Partners Inc., based on Form 13F filings with the SEC.

News

Stay updated on Polar Asset Management Partners Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email